METABOLIC DISORDERS DRUGS INDUSTRY MARKET ANALYSIS BY TYPE, APPLICATION, REGIONS AND COMPANIES FORECAST

  2024-11-27 |   Pages: 200+ |   Report ID: MD-R-2024-11-27-160971 |   Pharmaceuticals

Historical data: 2018 - 2023

Forecast period: 2024 - 2031

Quantitative units: Revenue in USD million and CAGR from 2024 to 2031

Report coverage: Revenue forecast, company ranking, competitive landscape, growth factors, and trends

Metabolic Disorders Drugs Industry Market

Image

1.1 SCOPE OF THE REPORT

1.2 MARKET SEGMENT ANALYSIS

1.3 REGULATORY SCENARIO BY REGION/COUNTRY

1.4 MARKET INVESTMENT SCENARIO STRATEGIC

1.5 MARKET ANALYSIS BY TYPE (USD MILLION)

1.6 MARKET ANALYSIS BY APPLICATION (USD MILLION)

2.1 DRIVER, RESTRAINT, CHALLENGE AND OPPORTUNITIES ANALYSIS

  2.1.1 MARKET DRIVER ANALYSIS

  2.1.2 MARKET RESTRAINT ANALYSIS

  2.1.3 MARKET OPPORTUNITY

  2.1.4 MARKET CHALLENGES

3.1 INDUSTRY TRENDS

  3.1.1 SWOT ANALYSIS

  3.1.2 PESTEL ANALYSIS

  3.1.3 PORTER’S FIVE FORCES ANALYSIS

3.2 POTENTIAL MARKET AND GROWTH POTENTIAL ANALYSIS

4.1 COVID-19 ANALYSIS

5.1 GLOBAL METABOLIC DISORDERS DRUGS INDUSTRY MARKET, SALES AREA, TYPE

5.2 MERGERS & ACQUISITIONS, PARTNERSHIPS, PRODUCT LAUNCH, AND COLLABORATION IN GLOBAL METABOLIC DISORDERS DRUGS INDUSTRY MARKET

7.1 GLOBAL METABOLIC DISORDERS DRUGS INDUSTRY MARKET SIZE AND SHARE (2018-2031) (USD MILLION)

8.1 GLOBAL METABOLIC DISORDERS DRUGS INDUSTRY MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)

8.2 GLOBAL METABOLIC DISORDERS DRUGS INDUSTRY MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)

9.1 GLOBAL METABOLIC DISORDERS DRUGS INDUSTRY MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)

9.2 GLOBAL METABOLIC DISORDERS DRUGS INDUSTRY MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)

10.1 GLOBAL METABOLIC DISORDERS DRUGS INDUSTRY MARKET SIZE AND SHARE BY REGION (2018-2023) (USD MILLION)

10.2 GLOBAL METABOLIC DISORDERS DRUGS INDUSTRY MARKET SIZE AND SHARE BY REGION (2024-2031) (USD MILLION)

11.1 NORTH AMERICA METABOLIC DISORDERS DRUGS INDUSTRY MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)

11.2 NORTH AMERICA METABOLIC DISORDERS DRUGS INDUSTRY MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)

11.3 NORTH AMERICA METABOLIC DISORDERS DRUGS INDUSTRY MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)

11.4 NORTH AMERICA METABOLIC DISORDERS DRUGS INDUSTRY MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)

11.5 NORTH AMERICA METABOLIC DISORDERS DRUGS INDUSTRY MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)

11.6 NORTH AMERICA METABOLIC DISORDERS DRUGS INDUSTRY MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)

12.1 EUROPE METABOLIC DISORDERS DRUGS INDUSTRY MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)

12.2 EUROPE METABOLIC DISORDERS DRUGS INDUSTRY MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)

12.3 EUROPE METABOLIC DISORDERS DRUGS INDUSTRY MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)

12.4 EUROPE METABOLIC DISORDERS DRUGS INDUSTRY MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)

12.5 EUROPE METABOLIC DISORDERS DRUGS INDUSTRY MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)

12.6 EUROPE METABOLIC DISORDERS DRUGS INDUSTRY MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)

13.1 ASIA PACIFIC METABOLIC DISORDERS DRUGS INDUSTRY MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)

13.2 ASIA PACIFIC METABOLIC DISORDERS DRUGS INDUSTRY MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)

13.3 ASIA PACIFIC METABOLIC DISORDERS DRUGS INDUSTRY MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)

13.4 ASIA PACIFIC METABOLIC DISORDERS DRUGS INDUSTRY MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)

13.5 ASIA PACIFIC METABOLIC DISORDERS DRUGS INDUSTRY MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)

13.6 ASIA PACIFIC METABOLIC DISORDERS DRUGS INDUSTRY MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)

14.1 LATIN AMERICA METABOLIC DISORDERS DRUGS INDUSTRY MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)/p>

14.2 LATIN AMERICA METABOLIC DISORDERS DRUGS INDUSTRY MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)

14.3 LATIN AMERICA METABOLIC DISORDERS DRUGS INDUSTRY MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)

14.4 LATIN AMERICA METABOLIC DISORDERS DRUGS INDUSTRY MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)

14.5 LATIN AMERICA METABOLIC DISORDERS DRUGS INDUSTRY MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)

14.6 LATIN AMERICA METABOLIC DISORDERS DRUGS INDUSTRY MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)

15.1 MIDDLE EAST & AFRICA METABOLIC DISORDERS DRUGS INDUSTRY MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)

15.2 MIDDLE EAST & AFRICA METABOLIC DISORDERS DRUGS INDUSTRY MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)

15.3 MIDDLE EAST & AFRICA METABOLIC DISORDERS DRUGS INDUSTRY MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)

15.4 MIDDLE EAST & AFRICA METABOLIC DISORDERS DRUGS INDUSTRY MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)

15.5 MIDDLE EAST & AFRICA METABOLIC DISORDERS DRUGS INDUSTRY MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)

15.6 MIDDLE EAST & AFRICA METABOLIC DISORDERS DRUGS INDUSTRY MARKET SIZE AND SHARE BY APPLICATION (2024-2031)< (USD MILLION)/p>

16.1 Exelixis Inc

  16.1.1 COMPANY DETAILS

  16.1.2 FINANCIALS (USD MILLION)

  16.1.3 PRODUCT SUMMARY

  16.1.4 RECENT DEVELOPMENTS

16.2 Pronutria Biosciences

16.3 Mitobridge

16.4 CellCentric

16.5 MedGenome

16.6 Zealand Pharma

16.7 Biophytis

16.8 Zafgen

16.9 Verva Pharmaceuticals

16.10 OxThera

16.11 Rhythm

16.12 Anchor Therapeutics

16.13 PerkinElmer

16.14 Biophytis

16.15 Nimbus Therapeutics

16.16 Eternygen

16.17 Outpost Medicine

18.1 METHODOLOGY

18.2 RESEARCH DATA SOURCE

  18.2.1 SECONDARY DATA

  18.2.2 KEY DATA FROM SECONDARY

  18.2.3 PRIMARY DATA

  18.2.4 KEY DATA FROM PRIMARY

  18.2.5 INDUSTRY INSIGHT FROM PROFESSIONAL LEADERS

  18.2.6 MARKET ESTIMATION

  18.2.7 MARKET ESTIMATION: TOP-DOWN AND BOTTOM-UP APPROACH

  18.2.8 LEGAL DISCLAIMER

Market Segments

Market by Type :

Tablet
Injection

Market by Application :

Diabetes
Disorders of the Thyroid and Pituitary Gland
Other

Companies

Exelixis Inc
Pronutria Biosciences
Mitobridge
CellCentric
MedGenome
Zealand Pharma
Biophytis
Zafgen
Verva Pharmaceuticals
OxThera
Rhythm
Anchor Therapeutics
PerkinElmer
Biophytis
Nimbus Therapeutics
Eternygen
Outpost Medicine

Single User License  : 3900$
Corporate License    : 7800$
Enquiry Before Buying
Request For Customization
Speak To Analyst

BROWSE INDUSTRY

  1. Consumer Goods
  2. Healthcare
  3. Food & Beverage
  4. Heavy Industry
  5. Service Industries
  6. FMCG
  7. Life Sciences
  8. Technology & Media
  9. Machinery & Equipment

    WHY CHOOSE US

  •   PROACTIVE

    • We manage our resources 24/7 to identify issues and address them before they become problems.

  •   QUALITY & RELIABILITY

    • We are committed to providing reliable and highly accurate data with an excellent quality control system.

  •   GLOBAL OUTREACH

    • 6 Major regions and 40+ countries level analysis accomplished.

  •   COMPETITIVE PRICING

    • Our pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery.